Relatively low primary resistance to anti-tuberculosis drugs in Bangui and Bimbo, Central African Republic

Int J Tuberc Lung Dis. 2011 May;15(5):657-61. doi: 10.5588/ijtld.10.0292.


Setting: The Central African Republic (CAR) is a country with a high burden of tuberculosis (TB). Although its national tuberculosis programme is effective, there is no continuous surveillance system for anti-tuberculosis drug resistance in place.

Objective: To establish base-line anti-tuberculosis drug resistance data to allow for future monitoring of trends and evolutions. More specifically, we aimed at investigating primary anti-tuberculosis drugs in Bangui and Bimbo, two cities of CAR.

Method: A total of 225 Mycobacterium tuberculosis isolates were tested for susceptibility to the anti-tuberculosis drugs commonly used in the country (isoniazid [INH, H], rifampicin [R], streptomycin [SM, S] and ethambutol [EMB, E]). Human immunodeficiency virus co-infection was recorded.

Results: Overall primary drug resistance was found to be 14.7% (33/225). The highest rate of primary resistance was for INH (9.3%), followed by SM (8.4%), and EMB (2.2%). The multidrug resistance rate was 0.4%.

Conclusion: Our study indicates that primary drug resistance levels in urban settings of CAR are similar to or lower than in other African cities, and that the spread of multidrug-resistant TB in this population is limited. Extended nationwide monitoring of drug resistance remains important, especially in view of the planned introduction of a new treatment regimen (2HRZE/4HR [Z = pyrazinamide]).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antitubercular Agents / pharmacology*
  • Central African Republic / epidemiology
  • Child
  • Child, Preschool
  • Drug Resistance, Bacterial
  • Female
  • HIV Infections / epidemiology
  • Humans
  • Infant
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Tuberculosis / epidemiology*
  • Tuberculosis / microbiology
  • Tuberculosis, Multidrug-Resistant / epidemiology*
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Young Adult


  • Antitubercular Agents